Celastrol treatment mitigates obesity-induced metabolic dysfunctions by enhancing insulin sensitivity in skeletal muscle via upregulation of GLUT4, improvement of mitochondrial function, and activation of antioxidant defense mechanisms (Abu Bakar et al., 2020). Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.